Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES)-Reference-Cited by-同舟云学术

Late toxicity within a Phase III clinical trial of IG-IMRT in cervix cancer (PARCER): Reanalysis with time weighted adverse event reporting (MOSES)

Published:2022-12 Issue: Volume:177 Page:16-20
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Supriya Chopra,Nilesh Ranjan,Mayuri Charnalia,Sadhana Kannan,Reena Engineer,Tapas Dora,Lavanya Gurram,Prachi Mittal,Amita Maheshwari,Shylasree T.S.,Shyam Shrivastava,Sudeep Gupta

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference6 articles.

1. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial;Chopra;J Clin Oncol,2021

2. Improvement in patient-reported outcomes with intensity-modulated Radiotherapy (RT) compared with standard RT: a report from the NRG Oncology RTOG 1203 study;Yeung;J Clin Oncol,2020

3. A comparative analysis of quality of life after postoperative intensity-modulated Radiotherapy or three-dimensional conformal Radiotherapy for cervical cancer;Mohanty;Indian J Cancer,2018

4. Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials;Ranjan;EClinicalMedicine,2022

5. Temporal course of late rectal toxicity & impact of intervention in patients undergoing radiation for cervical cancer;Shejul;Indian J Med Res,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensity-Modulated Radiation Therapy for Uterine Cervical Cancer to Reduce Toxicity and Enhance Efficacy – an Option or a Must?: A Narrative Review;Cancer Research and Treatment;2024-01-15

2. Hypothyroidism following Radiotherapy for Head and Neck Cancer: A Systematic Review of the Literature and Opportunities to Improve the Therapeutic Ratio;Cancers;2023-08-29

3. OncoFlash January 2023;Clinical Oncology;2023-01